Trials / Completed
CompletedNCT01723228
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 170 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2015-01-01
- Completion
- 2015-01-01
- First posted
- 2012-11-07
- Last updated
- 2021-11-09
- Results posted
- 2016-03-21
Locations
40 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01723228. Inclusion in this directory is not an endorsement.